Coya Therapeutics to Participate in Investor Conferences in September

Coya Therapeutics, a biotechnology company, will participate in two investor conferences in September. The management team will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11. Interested parties can meet with the team for one-on-one meetings.

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on developing biologics to enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, will participate in two investor conferences in September. The management team will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11. Interested parties can meet with the team for one-on-one meetings.

The H.C. Wainwright 27th Annual Global Investment Conference will be held on September 10, 2025, at the Lotte New York Palace Hotel in New York City. CEO Arun Swaminathan, Ph.D., will deliver a presentation [1]. The webcast will be accessible from the Company's website at https://coyatherapeutics.com/ under the Investor Relations section - Events and Presentations.

The Lake Street Capital Markets 9th Annual Best Ideas Growth Conference will be held on September 11, 2025, at The Yale Club of New York City. The management team will be available for one-on-one meetings during the conference. For more information and to arrange one-on-one meetings, contact your banking representatives directly or refer to the Achieve Life Sciences Investor Relations website [2].

Coya Therapeutics is developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. The company's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

The live and archived webcast for the H.C. Wainwright conference will be accessible for 90 days from the Company's website. For more details, visit www.coyatherapeutics.com.

References:
[1] https://www.marketscreener.com/news/coya-therapeutics-to-participate-at-upcoming-september-investor-conferences-ce7d59dbd98af22c
[2] https://ir.achievelifesciences.com/news-events/press-releases/detail/237/achieve-life-sciences-announces-participation-at-upcoming-investor-conferences